TLDR NAG-1 may help prevent some metabolic issues related to PCOS.
The study investigated the effects of NAG-1 overexpression on metabolic disorders associated with polycystic ovary syndrome (PCOS) in mice. PCOS was induced in mice using dihydrotestosterone (DHT) implants, and the subjects were monitored for 90 days. The results showed that NAG-1 overexpression did not affect weight or adipocyte sizes, indicating a potential prevention of hormonally induced obesity. However, DHT-treated mice exhibited earlier puberty, disrupted estrus cycles, and altered ovarian function, with fewer corpus lutea observed. Overall, the findings suggested that NAG-1 might prevent some metabolic dysfunctions linked to PCOS.
1265 citations
,
October 2013 in “The Journal of Clinical Endocrinology and Metabolism” The guideline suggests using specific criteria to diagnose PCOS, recommends various treatments for its symptoms, and advises screening for related health issues.
19 citations
,
July 2013 in “The obstetrician & gynaecologist” The document concludes that careful evaluation is needed to diagnose PCOS correctly due to similar symptoms in other conditions, and accurate testosterone level measurement is crucial.
815 citations
,
April 2010 in “The Journal of Clinical Endocrinology & Metabolism” Women with PCOS should be screened for heart disease risk and manage their health to prevent it.
4809 citations
,
January 2004 in “Fertility and Sterility” The 2003 consensus updated PCOS diagnosis criteria and highlighted increased risks of diabetes and heart disease for those affected.
1514 citations
,
December 2011 in “Fertility and sterility” Experts agree that PCOS affects women's health in complex ways, but more research is needed to understand and treat it effectively.
22 citations
,
January 2015 in “BioMed Research International” More adolescent girls in urban areas of India have Polycystic Ovary Syndrome compared to those in rural areas.
7 citations
,
March 2011 in “Expert Opinion on Drug Safety” Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
September 2025 in “Reproductive health of woman” Metformin reduces high male hormone levels in women with PCOS.
3 citations
,
March 2017 in “Regulatory toxicology and pharmacology” Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.